drugset / Trial / NCT03472495

Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial

NCT03472495

Phase 4 Completed 19 enrolled Virginia Commonwealth University
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to compare the incidence of rate control (defined as: HR \<110 beats/min or conversion to sinus rhythm) at 2 hours after medication administration between oral immediate release diltiazem and intravenous continuous infusion diltiazem.

Timeline

Start
2018-06-01
Primary completion
2021-03-21
Completion
2021-03-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diltiazem Small molecule 2.5 mg Oral
Comparator Diltiazem Small molecule 5 mg Oral
Comparator Diltiazem Small molecule 15 mg Oral
Comparator Diltiazem Small molecule 30 mg Oral
Comparator Diltiazem Small molecule 60 mg Oral